Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MAB5320 Anti-Synuclein α Antibody, clone 7B12.2

MAB5320
100 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
HIHC, WBMCulture SupernatantMonoclonal Antibody
Description
Catalogue NumberMAB5320
Replaces04-1053
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Synuclein α Antibody, clone 7B12.2
References
Product Information
FormatCulture Supernatant
Control
  • Brain tissue
PresentationUnPurified tissue culture supernatant from a perfusion system, filtered through a 0.2μ micron membrane prior to vialing. Product contains 20%FBS and Ciprofloxacin at final concentration of 10μg/mL.
Quality LevelMQ100
Applications
ApplicationAnti-Synuclein Antibody, α, clone 7B12.2 detects level of Synuclein & has been published & validated for use in IH & WB.
Key Applications
  • Immunohistochemistry
  • Western Blotting
Application NotesWestern blotting on recombinant alpha synuclein: 1:2,000-1:4,000.

Lane 1: Recombinant human alpha synuclein

Lane 2: Recombinant human beta synuclein

Lane 3: Recombinant human gamma synuclein

Immunohistochemistry (frozen sections): 1:250-1:500

Optimal working dilutions must be determined by end user.
Biological Information
ImmunogenRecombinant human alpha synuclein.
Clone7B12.2
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostMouse
SpecificityReacts with alpha Synuclein. By Western blot the antibody shows no reactivity with beta or gamma synuclein. This antibody was shown to stain Lewy bodies in frozen section of human brain with Parkinson's disease and glial inclusions in frozen section of human brain with Multiple System Atrophy.
IsotypeIgG
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Entrez Gene SummaryAlpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
Gene Symbol
  • SNCA
  • PD1
  • alpha-synuclein
  • NACP
  • PARK4
  • MGC110988
  • PARK1
  • Alpha-synuclein
Purification MethodUnpurified
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P37840 # May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.
SIZE: 140 amino acids; 14460 Da
SUBUNIT: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
SUBCELLULAR LOCATION: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
TISSUE SPECIFICITY: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
DOMAIN: SwissProt: P37840 The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. & Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. & Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
DISEASE: SwissProt: P37840 # Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. & Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. & Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. & Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.
SIMILARITY: Belongs to the synuclein family.
Molecular Weight15-18 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
MAB5320 04053252578250

Documentation

Anti-Synuclein α Antibody, clone 7B12.2 MSDS

Title

Safety Data Sheet (SDS) 

Anti-Synuclein α Antibody, clone 7B12.2 Certificates of Analysis

TitleLot Number
MOUSE ANTI-ALPHA SYNUCLEIN MONOCLONAL ANTIBODY - 2433413 2433413
MOUSE ANTI-ALPHA SYNUCLEIN - 3326696 3326696
MOUSE ANTI-ALPHA SYNUCLEIN - 3328900 3328900
MOUSE ANTI-ALPHA SYNUCLEIN - 3800088 3800088
MOUSE ANTI-ALPHA SYNUCLEIN - 3899490 3899490
MOUSE ANTI-ALPHA SYNUCLEIN - 4085571 4085571
MOUSE ANTI-ALPHA SYNUCLEIN -2786062 2786062
MOUSE ANTI-ALPHA SYNUCLEIN MONOCLONAL ANTIBODY 3112662
MOUSE ANTI-ALPHA SYNUCLEIN MONOCLONAL ANTIBODY 3003760
MOUSE ANTI-ALPHA SYNUCLEIN MONOCLONAL ANTIBODY - 2167155 2167155

References

Reference overviewPub Med ID
Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease.
McCollum, MH; Leon, RT; Rush, DB; Guthrie, KM; Wei, J
Brain research  1518  91-103  2013

Show Abstract
23623813 23623813
Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease.
Kim, YH; Rane, A; Lussier, S; Andersen, JK
Journal of neuroscience research  89  1666-75  2010

Show Abstract
21710541 21710541
Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.
Kristina R Patterson,Christine Remmers,Yifan Fu,Sarah Brooker,Nicholas M Kanaan,Laurel Vana,Sarah Ward,Juan F Reyes,Keith Philibert,Marc J Glucksman,Lester I Binder
The Journal of biological chemistry  286  2010

Show Abstract
21550980 21550980

Related Products & Applications

Related Products

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies